BMS submits marketing applications for entecavir to treat HBV in US and Europe

6 November 2004. Related: Hepatitis coinfection.

Bristol-Myers Squibb Company has announced the submission of a New Drug Application to the US Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.

The company also submitted a marketing authorisation application for entecavir to the European Medicines Evaluation Agency.

Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.

Source: BMS press release

http://www.bms.com/news/press/data/fg_press_release_5036.html